Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Catena: Breaking the chain

While antiangiogenics targeting VEGF have transformed treatment of some cancers and age-related macular degeneration, their use is associated with side effects including bleeding and gastrointestinal perforation. Catena Pharmaceuticals Inc. believes inhibiting signaling by lysophosphatidic acid, which has a different mechanism of action in angiogenesis as well as other biologic activity, could be safer than VEGF inhibition and may more specifically target some diseases.

Catena's lead molecule is VPC51299,

Read the full 679 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE